Thomas AJ, et al. - This study sought to ascertain the effectiveness of 3 commercially available botulinum toxin neuromodulators in the treatment of facial synkinesis. For facial synkinesis management, abobotulinumtoxinA indicated similar efficacy to onabotulinumtoxinA and incobotulinumtoxinA up to 4 weeks after treatment. IncobotulinumtoxinA seemed to have significantly less effect on Synkinesis Assessment Questionnaire (SAQ) score improvement than onabotulinumtoxinA at 4 weeks, perhaps because of the shorter duration of action. When using incobotulinumtoxinA treatment for facial synkinesis, shorter intervals between treatments or larger doses might be required.